Literature DB >> 19047655

Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.

F Lamoth1, T Buclin, C Csajka, A Pascual, T Calandra, O Marchetti.   

Abstract

Imipenem plasma concentrations were analyzed in 57 febrile neutropenic patients using the NONMEM program. The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19047655      PMCID： PMC2630622          DOI： 10.1128/AAC.00891-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

3.  Pharmacodynamics of cefepime in patients with Gram-negative infections.

Authors:  Vincent H Tam; Peggy S McKinnon; Ronda L Akins; Michael J Rybak; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

4.  Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.

Authors:  R M Janmohamed; M J Leyland; J Kelly; I Farrell
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

5.  Tissue distribution of imipenem in critically ill patients.

Authors:  Irmgard Tegeder; Achim Schmidtko; Lutz Bräutigam; Andreas Kirschbaum; Gerd Geisslinger; Jörn Lötsch
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

6.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Increased aminoglycoside dosage requirements in hematologic malignancy.

Authors:  R G Zeitany; N S El Saghir; C R Santhosh-Kumar; M A Sigmon
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.

Authors:  G L Drusano; K I Plaisance; A Forrest; C Bustamante; A Devlin; H C Standiford; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

9.  Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients.

Authors:  B A Zajac; M A Fisher; G A Gibson; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 10.  The pharmacodynamics of beta-lactams.

Authors:  J D Turnidge
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079
View more
  8 in total

1.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Antibiotic therapy in hematological neutropenic patients: what is the news?

Authors:  F Pea
Journal:  Leuk Suppl       Date:  2012-08-09

Review 5.  Implications of augmented renal clearance in critically ill patients.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

6.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

7.  Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study.

Authors:  Pier Giorgio Cojutti; Davide Lazzarotto; Anna Candoni; Maria Vittoria Dubbini; Maria Elena Zannier; Renato Fanin; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

Review 8.  Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Crit Care       Date:  2009-06-10       Impact factor: 9.097
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.